National Programme —

Rapid Uptake Products

Supporting stronger adoption and spread of proven innovations.

Female healthcare worker sits at desk talking on video call to patient through mobile phone
Programme
Overview

The Rapid Uptake Products Programme (RUP) identifies and supports products that are in-line with the NHS Long Term Plan’s key clinical priorities but have lower than expected uptake to date.


Products are NICE approved. 


There is an open selection process. The list of Rapid Uptake Products are updated annually. 

Detailed Programme Information

The Rapid Uptake Products (RUP) programme identifies and supports products with the National Institute for Health and Care Excellence (NICE) approval that support the NHS Long Term Plan’s key clinical priorities but have lower than expected uptake to date.  

The AHSN Network is a key member of the Accelerated Access Collaborative (AAC), the umbrella organisation for UK health innovation, the front door to support for innovators and sets the strategy for a more effective innovation ecosystem.  

Current projects in the programme for 2021/22 include:

Lipid management – High Intensity Statins, Ezetimibe and PCSK9 inhibitors 

The RUP for lipid management is a novel, NICE-endorsed clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine along the evidence-based pathway. The pathway includes a number of medicines. 

Asthma diagnosis – Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma 

FeNO (fractional exhaled nitric oxide) is a point of care test to measure type two inflammation in airways, which augments and supports the accuracy of asthma diagnosis. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma. 

We are hosting five regional collaborative forums to support the implementation of FeNO testing in South West England. Each forum is an opportunity to hear from South West respiratory leads and clinical champions about their experience and recommendations for implementing FeNO.

Asthma treatment – Biological therapies to reduce side-effects 

Biological therapies can transform patient lives by reducing long-term side effects of other treatments (e.g. oral corticosteroids (OCS)) and can also reduce the number of exacerbations and life-threatening asthma attacks. The aim of this innovation will be to improve patient care and outcomes by providing a better treatment option for patients with severe asthma. 

Funding is available to the entire South West of England, from Cornwall to Swindon. The South West Severe Asthma Network will work with all hospitals to create a common pathway for managing asthma care streamlining the process of referral to severe asthma centres and access to asthma biologic therapy.

For more information, please contact the South West AHSN’s RUP lead and Programme Manager, Steve Johnson-Wood. 

Get Involved icon

Get involved

For all upcoming events, please see our Events page

Learn more

You may also be interested in

Rapid Uptake Products

Video: First FeNO forum held in November 2021

Watch now
Rapid Uptake Products

Health Innovation podcast: Game changer therapy for severe asthma sufferers

Listen now
Rapid Uptake Products

Health Innovation podcast: How a new test is improving asthma care

Listen now
Newsletter

Stay up to date

Sign up to our newsletter for all the latest news and events